Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
about
Evolutionary dynamics of cancer in response to targeted combination therapyAnaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphomaCancer genome landscapesThird-line systemic treatment for non-small cell lung cancerDesign and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies.MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signalingALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastomaTrials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and FutureAnaplastic thyroid cancers harbor novel oncogenic mutations of the ALK geneEpidemiology of lung cancerGenetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer MedicineCrizotinib: A comprehensive reviewClinical use of crizotinib for the treatment of non-small cell lung cancerCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsCrizotinib resistance: implications for therapeutic strategiesThe role of the ALK receptor in cancer biologyCrizotinib: from discovery to accelerated development to front-line treatmentALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncologyPersonalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker SelectionTargeted therapies and immunotherapy in non-small-cell lung cancerTackling ALK in non-small cell lung cancer: the role of novel inhibitorsNon-small cell lung cancer: current treatment and future advancesCancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesTyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farNew treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinibRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCPractical aspects of NGS-based pathways analysis for personalized cancer science and medicineRole of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patientsMolecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomasTargeting hypoxic response for cancer therapyOncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesMolecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsRole of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present eraALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceNew strategies in immunotherapy for non-small cell lung cancerLung cancer biomarkers, targeted therapies and clinical assaysPersonalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
P2860
Q21128788-F6DE48F6-825C-40BD-9661-AF6AA5B72DDCQ21285042-695FC0A8-56ED-4408-BFC7-2131D3EDC4FAQ22242276-A5DB762E-D5A2-4F79-9353-EDBF2D13D537Q24194090-94588726-E383-4C28-BB76-880D0EF97152Q24289207-D9B4FED3-1DDB-4CE4-9226-6F507C06529DQ24304423-1FC74470-BEB4-4200-90AA-7080E38277ABQ24310296-9D381FEA-0FEB-4A40-95E3-B76BF879E078Q24564024-92E7777E-5986-4274-A90B-B0D80BEF18A7Q24598210-8F5C4677-30DA-4257-BDC3-570861C89AA8Q24600475-368CE22B-43BE-4545-BAB4-DFAAA7FA277BQ24604479-EA196AFB-EB78-4F62-AFC0-A9DFC812058AQ24624083-3E4C31C3-A37D-471E-9A97-9BCC433DD906Q24630466-E4377445-0DF9-4DB3-B734-5DF3F56ACF98Q24632064-F5CBF388-F144-4828-A608-E9DA58A21517Q26738381-F6AD0DD8-EC0F-4B79-99C4-B75953366E42Q26738384-4C222E77-F0B3-4D8F-B526-A39151C05A22Q26738385-5718EE47-BB1B-44B5-816C-C748CCA049F1Q26738387-E27C38EF-FA02-47FD-AE87-753213564B01Q26738860-4F10CD1D-90A5-4EA2-9963-03F6B491204BQ26738986-B7464E1F-1E4B-476E-A958-D633ABBD4D09Q26740329-2F8A6727-AB30-4D9D-B26E-A8515223C36EQ26740333-402D5088-3663-4E9D-92A5-C0EB3A79EEF1Q26741009-85E81C27-DC3B-4D32-B629-5DA94BDF983BQ26741318-40C03609-4010-41F1-B50A-3A8047E8F25AQ26741814-B4C13F6C-7FA6-4E9A-A618-1A0B8466FCCAQ26745776-B782695C-3726-417A-88D3-BE6BE834CBDFQ26746230-C4D8DD72-195E-49A1-B29E-97855A656FD1Q26747276-69D313FC-2CD6-4FFF-9A04-DB96AA2DE69AQ26748603-360A3CA8-3472-4F1D-A784-E2C0A440F238Q26750428-C7C6CEA2-DB93-4F35-8323-3D908C18018CQ26752945-8B6B233B-BA50-49E0-8CC8-BE075C87A664Q26767351-0AA5E978-031A-4A7A-A652-A3BDD150AB6FQ26768158-3C1DE2EA-0EE1-40F1-AE7B-6F11D4CDC846Q26769659-7F6FCF13-EA4B-41C8-9BFD-5834172B08FBQ26769879-927E3A86-95BE-4F59-8F92-91BF7E2FAB50Q26774726-5C707144-EB57-4C8A-B5C3-87AF2185E5CBQ26775347-D565C557-88BB-4F50-A21C-2A90F9305163Q26775385-B9ED8930-CA44-4126-A096-D0639D76C715Q26775396-15B733E7-4369-4B89-B160-3553919E0019Q26775817-D20E0BA7-FADD-4EA9-AC14-7A7E88F2751A
P2860
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
@ast
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
@en
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
@nl
type
label
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
@ast
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
@en
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
@nl
altLabel
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
@en
prefLabel
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
@ast
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
@en
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
@nl
P2093
P2860
P50
P3181
P356
P1476
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
@en
P2093
A John Iafrate
Alice T Shaw
Benjamin Solomon
Bruce J Dezube
D Ross Camidge
Daniel A Haber
Eunice L Kwak
Geoffrey I Shapiro
Greg C Wei
Hannah Stubbs
P2860
P304
P3181
P356
10.1056/NEJMOA1006448
P407
P5008
P577
2010-10-28T00:00:00Z